Screening for genetic risk of breast cancer

American Family Physician

Volumn 59, Issue 1, 1999, Pages 99-104

  Rosenthal, Thomas C ^a   Puck, Stirling M ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b GENZYME GENETICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; BREAST EXAMINATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HETEROZYGOTE DETECTION; HUMAN; MASTECTOMY; ONCOGENE; OVARIECTOMY;

ALGORITHMS; BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENES, BRCA1; GENES, TUMOR SUPPRESSOR; GENETIC SCREENING; HETEROZYGOTE; HUMANS; MUTATION; PATIENT EDUCATION; PRACTICE GUIDELINES; TEACHING MATERIALS;

EID: 0032920498     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30 [published erratum in CA Cancer J Clin 1995;45:127-8].
2. Newman B, Mu H, Butler LM, Milliken RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998;279:915-21.
3. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA. BRCA1 mutations and breast cancer in the general population. Analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 1998;279:922-9.
4. Struewing JR Hartge P Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
5. Ford D, Easton DF, Petro J. Estimates of the gene frequency of BRCA 1 and its contribution to breast and ovarian cancer incidence. Am J Human Genetics 1995;57:1457-62.
6. Struewing JR Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the BRCA 1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200 [published erratum in Nat Genet 1996;12:110].
7. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92 [published erratum in Nature 1996;379:749].
8. Claus EB, Schildkraut JM, Thompson WD, Risen NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-24.
9. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277: 997-1003.
10. Frame PS, Carlson SJ. A critical review of periodic health screening using specific screening criteria. J Fam Pract 1975;2:29-36,123-9,189-94,283-9.
11. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2d ed. Washington, D.C.: Superintendent of Documents, U.S. Government Printing Office, 1996.
12. Harris R, Leininger L. Clinical strategies for breast cancer screening: weighing and using the evidence. Ann Intern Med 1995;122:539-47.
13. Tabar L, Faberberg G, Day NE, Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-country breast cancer screening trial. Br J Cancer 1987;55:547-51.
14. Kopans DB. Interval breast cancers in the screening mammography program of British Columbia: analysis and classification [Letter]. AJR Am J Roentgenol 1995;164:1298-9.
15. King M, Rowell S, Love SM. Inherited breast and ovarian cancer: what are the risks? what are the choices? JAMA 1993;269:1975-80.
16. Couch FJ. BRCA1 testing - advances and retreats [Editorial]. JAMA 1998;279:955-6.
17. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, et al. A collaborative survey of 80 mutations in the BRCA 1 breast and ovarian cancer susceptibility gene JAMA 1995;273:535-41.
18. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-15.
19. Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA 1995;273:577-85.
20. Degner LF, Kristjanson LJ, Bowman D, Sloan JA, Carriere KC, O'Neil J, et al. Information needs and decisional preferences in women with breast cancer. JAMA 1997;277:1485-92.
21. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-71 [published erratum in N Engl J Med 1997;337:434].
22. Jordan VC. Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 1995;208:144-9.
23. McKinnon WC, Baty BJ, Bennett RL, Magee M, Neufeld-Kaiser WA, Peters KF, et al. Predisposition genetic testing for late-onset disorders in adults. A position paper of the National Society of Genetic Counselors. JAMA 1997;278:1217-20.